key: cord-1034859-hswaele8
authors: Monk, Bradley J.; Coleman, Robert L.; Moore, Kathleen N.; Herzog, Thomas J.; Secord, Angeles Alvarez; Matulonis, Ursula A.; Slomovitz, Brian M.; Guntupalli, Saketh R.; O'Malley, David M.
title: COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies
date: 2020-04-29
journal: Gynecol Oncol
DOI: 10.1016/j.ygyno.2020.04.703
sha: 917eb7e9014f50ac41f1aab53cb601a34f29a2f4
doc_id: 1034859
cord_uid: hswaele8

• The pandemic COVID-19 requires alternative methods and thinking to keep healthcare professionals and patients safe. • In COVID-19 hot spots, oral therapies may be viable alternatives to intravenous therapies for treatment of ovarian cancer. • Minimizing patient visits to hospitals and cancer clinics may help mitigate the spread of SARS-CoV-2.

J o u r n a l P r e -p r o o f

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. Epub ahead of print

National Comprehensive Cancer Network

Latest clinical evidence of maintenance therapy in ovarian cancer

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial